Neurocentrx Pharma, the Equity Gap portfolio company, were thrilled to see recruitment begin for the EDEN study, marking an important step in exploring oral ketamine as a potential treatment for patients living with both anorexia nervosa and treatment-resistant major depression.
This is a unique and highly vulnerable patient group with significant unmet clinical needs. We’re proud to continue supporting research that seeks to validate new therapeutic options in clinical psychiatry, helping to expand treatment possibilities for those who have not responded to existing therapies.
With funding from the UK Medical Research Council, our collaborators at King’s College London are leading pioneering studies into innovative approaches for improving care in mood disorders. Neurocentrx deeply value their expanding collaboration and look forward to sharing further updates as they work together to advance safe, scalable, and effective treatments for patients with severe mood disorders.